Prescient Therapeutics Ltd PTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.04
- Day Range
- A$0.04–0.04
- 52-Week Range
- A$0.04–0.11
- Bid/Ask
- A$0.04 / A$0.05
- Market Cap
- A$34.63 Mil
- Volume/Avg
- 416,982 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1
- Website
- https://www.ptxtherapeutics.com
Valuation
Metric
|
PTX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
PTX
|
---|---|
Quick Ratio | 9.03 |
Current Ratio | 10.26 |
Interest Coverage | — |
Quick Ratio
PTX
Profitability
Metric
|
PTX
|
---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gwbgppxqxl | Xkc | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xfbpthgb | Mmhzvq | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qkkvbtc | Fghsny | $106.7 Bil | |
MRNA
| Moderna Inc | Mbwkvjnx | Pqt | $50.9 Bil | |
ARGX
| argenx SE ADR | Wdkmzzd | Czjh | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Kxdpwqfy | Ngbj | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hmxcjtpk | Mznvz | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Prfwsmtxr | Mfwphdh | $14.6 Bil | |
INCY
| Incyte Corp | Mjrtplzw | Cnwqlk | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nwbfdhnqxy | Thfmw | $12.6 Bil |